HCW Biologics バランスシートの健全性
財務の健全性 基準チェック /06
HCW Biologics has a total shareholder equity of $-6.3M and total debt of $10.0M, which brings its debt-to-equity ratio to -159.1%. Its total assets and total liabilities are $26.8M and $33.1M respectively.
主要情報
-159.1%
負債資本比率
US$10.02m
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$1.16m |
| エクイティ | -US$6.30m |
| 負債合計 | US$33.12m |
| 総資産 | US$26.82m |
財務状況分析
短期負債: HCWB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
長期負債: HCWB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
デット・ツー・エクイティの歴史と分析
負債レベル: HCWB has negative shareholder equity, which is a more serious situation than a high debt level.
負債の削減: HCWB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: HCWB has less than a year of cash runway based on its current free cash flow.
キャッシュランウェイの予測: HCWB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.2% each year